US · Technology · Scientific & Technical Instruments
EPS came in at 2.21 against a street estimate of 2.55 — a miss of 13.3%.
Analysts rate Mesa Laboratories Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $125.00.
| Fund | Stake |
|---|---|
| Long Path Partners, LP | 8.53% |
| BlackRock Inc | 7.87% |
| Boston Partners Global Investors, Inc | 4.74% |
| Vanguard Capital Management, LLC | 4.24% |
| AQR Capital Management LLC | 3.64% |
| Ranger Investment Management LP | 3.11% |
| Morgan Stanley - Brokerage Accounts | 2.81% |
| Diamond Hill Capital Management, LLC | 2.78% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 FY2027 RESTRUCTURING ANNOUNCEMENT • Mesa Laboratories approved a restructuring program on October 6, 2026, with employee notifications beginning October 12, | 2026-10-13 |
| Shareholder vote results · Q2 FY2027 MESA LABORATORIES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held September 8, 2026 • 4,872,692 shares represented out o | 2026-09-08 |
| Quarterly report · Q1 FY2027 MESA LABORATORIES, INC. – Q2 FY2026 (Period Ended June 30, 2026) – 10-Q SUMMARY --- HEADLINE NUMBERS • Revenue: $60,138k for Q2 FY2026 vs. $59,543k | 2026-08-10 |
| Results announced · Q2 FY2027 MESA LABORATORIES, INC. — Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenues: $60,138k, up 1.0% year-over-year • Operating income: $7,031k | 2026-08-10 |
| Current report · Q2 FY2027 MESA LABORATORIES, INC. – FORM 8-K SUMMARY OTHER NOTABLE POINTS • Company updated and amended its Code of Ethics and Business Conduct effective July | 2026-07-30 |
| Proxy statement · Q2 FY2027 MESA LABORATORIES, INC. — PROXY STATEMENT SUMMARY CEO TOTAL COMPENSATION & CHANGE • Dr. Siddhartha Kadia was appointed President and Chief Executive | 2026-07-22 |
| Board / officer change · Q1 FY2027 MESA LABORATORIES, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Chief Accounting Officer appointment effective June 26, 2026 • Annual base salary: $32 | 2026-06-15 |
| Annual report FY2026 MESA LABORATORIES, INC. - 10-K SUMMARY HEADLINE NUMBERS • Fiscal year ended: March 31, 2026 • Stock trading: Nasdaq under symbol MLAB • Outstanding | 2026-06-03 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.16 / share ex-date Nov 30, 2026 · pay Dec 15, 2026 | 2026-11-30 |
| Dividend | $0.16 / share ex-date Aug 31, 2026 · pay Sep 15, 2026 | 2026-08-31 |
| Dividend | $0.16 / share ex-date May 29, 2026 · pay Jun 15, 2026 | 2026-05-29 |
| Dividend | $0.16 / share ex-date Feb 27, 2026 · pay Mar 16, 2026 | 2026-02-27 |
| Dividend | $0.16 / share ex-date Nov 28, 2025 · pay Dec 15, 2025 | 2025-11-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mesa Laboratories Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.